Tumor Biology

, Volume 36, Issue 2, pp 915–919 | Cite as

Crk-like adapter protein is required for TGF-β-induced AKT and ERK-signaling pathway in epithelial ovarian carcinomas

Research Article


Crk-like adapter protein (CrkL) was identified as an important biomarker in epithelial ovarian carcinomas. At the same time, the transforming growth factor β (TGF-β) pathway plays a key role in oncogenesis of advanced cancers. However, more detailed regulation mechanisms are still unclear. So we investigated the role of CrkL in TGF-β pathways in epithelial ovarian carcinomas. The small interfering RNA (siRNA) was used to suppress CrkL in serous papillary cystic adenocarcinoma (SKOV-3) cell line, TGF-β downstream signal molecules AKT and ERK phosphorylation status was tested using the Western blot. Wound healing assay was used to evaluate the capacity of cell migration and proliferation. In this study, CrkL can be activated by TGF-β1 treatment and inhibited by siCrkL. CrkL knockdown markedly suppressed the phosphorylated ERK (p-ERK) as well as the phosphorylated AKT (p-AKT) (p < 0.001) compared with control or TGF-β1 alone. On the other hand, CrkL knockdown could significantly affect SKOV3 wound closure (p < 0.001) using wound healing assay compared to siControl. In conclusion, CrkL protein is required for TGF-β signal pathways through AKT and ERK pathway, which can mediate the development of epithelial ovarian carcinomas. CrkL plays a key regulation role in TGF-β signaling pathway of epithelial ovarian carcinomas, and this study suggested CrkL could be suggested as an efficient target in ovarian cancer treatment.


CrkL TGF-β AKT ERK Epithelial ovarian carcinomas 



This work was supported by Science and Technology Project of Shandong Province Academy of Medical Sciences (2013015). We greatly thank other members of Sandy and Yang Lab for their valuable suggestions and writing.

Conflicts of interest



  1. 1.
    Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;S0140–6736:62146–7.Google Scholar
  2. 2.
    Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A. Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther. 2010;10:81–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Gynecologic oncology group incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Bell ES, Park M. Models of Crk adaptor proteins in cancer. Genes Cancer. 2012;3:341–52.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sriram G, Birge RB. Emerging roles for Crk in human cancer. Genes Cancer. 2010;1:1132–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRefGoogle Scholar
  8. 8.
    Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene. 2001;20:6348–71.CrossRefPubMedGoogle Scholar
  9. 9.
    Evren S, Ma XZ, Sakac D, Branch DR. SHP-1 protein tyrosine phosphatase associates with the adaptor protein CrkL. Exp Hematol. 2012;40:1055–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009;7:13.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA. TGF-β as a therapeutic target in high grade gliomas promises and challenges. Biochem Pharmacol. 2013;85:478–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Wick W, Naumann U, Weller M. Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. Curr Pharm Des. 2006;12:341–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Feller SM, Knudsen B, Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994;13:2341–51.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Fathers KE, Bell ES, Rajadurai CV, Cory S, Zhao H, Mourskaia A, et al. Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res. 2012;14:R74.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Morita T, Mayanagi T, Sobue K. Dual roles of myocardin-related transcription factors in epithelial mesenchymal transition via slug induction and actin remodeling. J Cell Biol. 2007;179:1027–42.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Shi YG, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefPubMedGoogle Scholar
  17. 17.
    Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A. 2001;98:6686–91.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem. 2000;275:36803–10.CrossRefPubMedGoogle Scholar
  19. 19.
    Cicchini C, Laudadio I, Citarella F, Corazzari M, Steindler C, Conigliaro A, et al. TGFbeta-induced EMT requires focal adhesion kinase (FAK) signaling. Exp Cell Res. 2008;314:143–52.CrossRefPubMedGoogle Scholar
  20. 20.
    Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem. 2001;276:46707–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia. 2004;6:603–10.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Porsch H, Bernert B, Mehic M, Theocharis AD, Heldin CH, Heldin P. Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene. 2013;32:4355–65.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhang H, Liu L, Wang Y, Zhao G, Xie R, Liu C, et al. KLF8 involves in TGF-beta-induced EMT and promotes invasion and migration in gastric cancer cells. J Cancer Res Clin Oncol. 2013;139:1033–42.CrossRefPubMedGoogle Scholar
  24. 24.
    Ding X, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor beta (TGF-beta) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem. 2013;288:10241–53.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001;12:27–36.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Thoelking G, Reiss B, Wegener J, Oberleithner H, Pavenstaedt H, Riethmuller C. Nanotopography follows force in TGF-beta1 stimulated epithelium. Nanotechnology. 2010;21:265102.CrossRefPubMedGoogle Scholar
  27. 27.
    Buckley ST, Medina C, Davies AM, Ehrhardt C. Cytoskeletal re-arrangement in TGF-beta1-induced alveolar epithelial-mesenchymal transition studied by atomic force microscopy and high-content analysis. Nanomedicine. 2012;8:355–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2002;2:301–14.CrossRefPubMedGoogle Scholar
  29. 29.
    Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK. MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer. 2008;99:520–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Shaomei Cheng
    • 1
  • Jingyan Guo
    • 2
  • Qing Yang
    • 3
  • Lin Han
    • 3
  1. 1.Department of GynecologyAffiliated Hospital of Shandong Academy of Medical SciencesJinanChina
  2. 2.Department of PharmacyAffiliated Hospital of Shandong Academy of Medical SciencesJinanChina
  3. 3.Department of MedicineAffiliated Hospital of Shandong Academy of Medical SciencesJinanChina

Personalised recommendations